Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients[...]

Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States

Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Gender differences in pain interference with daily activities and functional impairment[...]

Artificial Intelligence and Dermatology

Wongvibulsin S, Lee I. Artificial Intelligence and Dermatology. JAMA Dermatol. 2025 Jan 8. doi: 10.1001/jamadermatol.2024.4645. Epub ahead of print. PMID: 39774621.